Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.79 |
| ▸ | BCR | P11274 | 10/20 | 0.79 |
| ▸ | LYN | P07948 | 5/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.71 |
| ▸ | KIT | P10721 | 7/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.69 |
| ▸ | DDX3X | O00571 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654429 | 0.97 | ABL1 (0.79) | ABL1BCRLYNCCNA2CDK2 | |
| SCHEMBL3532229 | 0.94 | ABL1 (0.76) | ABL1BCRLYNKITPDGFRA | |
| SCHEMBL3526105 | 0.94 | ABL1 (0.75) | ABL1BCRLYNKITPDGFRA | |
| SCHEMBL5223561 | 0.92 | ABL1 (0.73) | ABL1BCRLYNKITPDGFRA | |
| SCHEMBL1654077 | 0.91 | ABL1 (0.72) | ABL1BCRLYNCCNA2CDK2 | |
| SCHEMBL1654184 | 0.91 | ABL1 (0.71) | ABL1BCRLYNCCNA2CDK2 | |
| SCHEMBL1653890 | 0.89 | ABL1 (0.69) | ABL1BCRLYNCCNA2CDK2 | |
| SCHEMBL3560947 | 0.88 | ABL1 (1.00) | ABL1BCRLYNKITPDGFRA | |
| SCHEMBL3536285 | 0.87 | ABL1 (0.76) | ABL1BCRLYNKITPDGFRA | |
| SCHEMBL3530875 | 0.86 | ABL1 (0.75) | ABL1BCRLYNKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | ABL1 197/4885BCR 1066/4885LYN 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.